OraSure Technologies, Inc. (NASDAQ:OSUR) Files An 8-K Results of Operations and Financial ConditionItem 2.02 – Results of Operations and Financial Condition.
|
Exhibit Number |
Description |
| 99.1 | Press Release, dated August2, 2017, announcing consolidated financial results of OraSure Technologies, Inc. for the quarter and six-month period ended June30, 2017, and providing financial guidance for the third quarter of 2017. |
| 99.2 | Prepared Remarks of Douglas A. Michels and Ronald H. Spair for OraSure Technologies, Inc. Second Quarter 2017 Analyst/ Investor Conference Call held August2, 2017. |
ORASURE TECHNOLOGIES INC ExhibitEX-99.1 2 d428806dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Company Contact: Ronald H. Spair Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com OraSure Announces 2017 Second Quarter Financial Results BETHLEHEM,…To view the full exhibit click here
About OraSure Technologies, Inc. (NASDAQ:OSUR)
OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Company also manufactures and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. Its diagnostic products include tests, such as OraQuick Rapid HIV Test, OraQuick In-Home HIV Test, OraQuick HIV Self-Test, OraQuick HCV Rapid Antibody Test, OraQuick Ebola Rapid Antigen Test, OraSure QuickFlu Rapid Flu A&B Test, OraSure Collection Device, Molecular Collection Systems, Cryosurgical Systems (Skin Lesion Removal Products), Immunoassay Tests and Reagents, Western blot HIV-1 Confirmatory Test and Q.E.D. Saliva Alcohol Test. Its products are sold in the United States and internationally to clinical laboratories and hospitals.